Contrasting of Sutro Biopharma Inc. (STRO) and Nabriva Therapeutics plc (NASDAQ:NBRV)

We will be contrasting the differences between Sutro Biopharma Inc. (NASDAQ:STRO) and Nabriva Therapeutics plc (NASDAQ:NBRV) as far as profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sutro Biopharma Inc. 23.37M 10.17 49.17M -2.21 0.00
Nabriva Therapeutics plc 9.98M 13.62 106.22M -2.31 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Sutro Biopharma Inc. and Nabriva Therapeutics plc.

Profitability

Table 2 shows us the net margins, return on assets and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
Sutro Biopharma Inc. -210.40% 0% 0%
Nabriva Therapeutics plc -1,064.33% -124.4% -107.4%

Liquidity

The Current Ratio and a Quick Ratio of Sutro Biopharma Inc. are 3.5 and 3.5. Competitively, Nabriva Therapeutics plc has 7.3 and 7.3 for Current and Quick Ratio. Nabriva Therapeutics plc’s better ability to pay short and long-term obligations than Sutro Biopharma Inc.

Insider and Institutional Ownership

Roughly 71.8% of Sutro Biopharma Inc. shares are owned by institutional investors while 57.1% of Nabriva Therapeutics plc are owned by institutional investors. Insiders owned 8.5% of Sutro Biopharma Inc. shares. Comparatively, Nabriva Therapeutics plc has 0.3% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sutro Biopharma Inc. 14.01% -8% 0% 0% 0% -21.32%
Nabriva Therapeutics plc 2.45% -10.68% -21.72% -52.17% -64.09% -65.05%

For the past year Sutro Biopharma Inc. was less bearish than Nabriva Therapeutics plc.

Summary

Sutro Biopharma Inc. beats Nabriva Therapeutics plc on 8 of the 10 factors.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.